Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans (Q28174827)

Europe PubMed Central

title

Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans (English)

0 references

1 reference

C J Hawkey

1

0 references

L Jackson

2

0 references

S E Harper

3

0 references

T J Simon

4

0 references

E Mortensen

5

0 references

C R Lines

Alimentary Pharmacology & Therapeutics

6

0 references

language of work or name

English

0 references

publication date

January 2001

0 references

published in

0 references

volume

15

0 references

issue

1

0 references

page(s)

1-9

0 references

cites work

Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use.

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2001.00894.X

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2001.00894.X

Recent considerations in nonsteroidal anti-inflammatory drug gastropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2001.00894.X

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2001.00894.X

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2001.00894.X

Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2001.00894.X

COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2001.00894.X

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2001.00894.X

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2001.00894.X

Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2001.00894.X

Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2001.00894.X